Key facts
- Foray’s last known valuation is $9.4M (Mar 2024).
- It has raised $3.4M; the latest was Seed Round in Mar 2026.
- Notable investors include Service Provider Capital, Greentown Labs, Harvard Innovation Launch Lab, SBXi, The Engine — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Foray
- ·The full record, as it builds
Funding rounds
No funding rounds for Foray are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Foray
Developer of bio-engineered products intended for plant-based products. The company uses plant cell culture, materials science, and tissue engineering to create viable alternatives to tree-sourced goods, enabling forest operators to generate the wood and forest products without cutting down trees.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Employees
- 17
- Website
- foraybio.com/
- Ownership
- Privately Held (backing)
Foray doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Foray shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Foray in its N-PORT filings yet. We sweep new filings monthly.